Ophthalmology – Juvenile Idiopathic Arthritis-Related Uveitis

Basics

Description

Juvenile idiopathic arthritis (JIA)-related uveitis is an important cause of chronic anterior uveitis in children with juvenile idiopathic arthritis.

JIA is defined as arthritis beginning before 16 years of age, persisting for more than 6 weeks, and occurring without another identifiable cause.

The major JIA categories include:

• Systemic arthritis
• Oligoarthritis
• Rheumatoid factor-negative polyarthritis
• Rheumatoid factor-positive polyarthritis
• Psoriatic arthritis
• Enthesitis-related arthritis
• Undifferentiated arthritis

Among these, oligoarticular JIA carries the greatest classic risk of chronic asymptomatic anterior uveitis.

A major clinical problem is that the eye may remain white and painless despite significant intraocular inflammation.

Epidemiology

The exact incidence and prevalence of JIA vary widely among populations.

Reported incidence ranges from approximately 0.008 to 0.226 per 1,000 children per year.

Reported prevalence ranges from approximately 0.07 to 4 per 1,000 children.

Uveitis develops in a minority of children with JIA, but the proportion varies substantially by population and JIA subtype.

Overall, approximately 8–10% of children with JIA develop uveitis, although individual studies have reported much wider ranges.

Risk Factors

Important risk factors for JIA-associated uveitis include:

• Positive ANA
• Young age at onset of arthritis
• Female sex
• Oligoarticular disease
• Early duration after JIA diagnosis

Children who develop arthritis at a younger age generally carry a greater risk than those with later-onset disease.

Genetics

JIA is genetically complex.

Certain HLA associations have been reported.

HLA-DRB1 alleles have been linked with susceptibility to JIA, and some studies have associated HLA-DRB1*13 with increased risk of uveitis.

No single genetic abnormality explains JIA-related uveitis.

Pathophysiology

The exact mechanism is not fully understood.

JIA is considered an immune-mediated inflammatory disease involving abnormal regulation of both innate and adaptive immunity.

Autoantibodies such as:

• ANA
• Rheumatoid factor
• Anti-cyclic citrullinated peptide antibodies

may be present in some patients, but the exact ocular antigen responsible for uveitis remains unknown.

Persistent inflammation within the anterior chamber can damage multiple ocular structures over time.

Etiology

The precise cause is unknown.

JIA-related uveitis is believed to result from a combination of:

• Genetic susceptibility
• Immune dysregulation
• Environmental triggers

JIA Subtypes

Systemic JIA

Systemic arthritis involves one or more joints with fever and may be associated with:

• Evanescent rash
• Generalized lymphadenopathy
• Hepatomegaly
• Splenomegaly
• Serositis

This subtype has a relatively low risk of chronic uveitis.

Oligoarthritis

Oligoarthritis affects 1–4 joints during the first 6 months.

It is divided into:

• Persistent oligoarthritis
• Extended oligoarthritis

This subtype is particularly important because it carries one of the highest risks of chronic asymptomatic uveitis.

Polyarthritis

Polyarthritis affects 5 or more joints during the first 6 months.

It is divided into:

• RF-negative polyarthritis
• RF-positive polyarthritis

Uveitis risk is generally lower than in oligoarticular JIA.

Psoriatic Arthritis

This category includes arthritis with psoriasis or arthritis associated with features such as:

• Dactylitis
• Nail pitting
• Onycholysis
• First-degree relative with psoriasis

Uveitis can occur.

Enthesitis-Related Arthritis

ERA is associated with inflammation at tendon or ligament insertions.

Features may include:

• Sacroiliac tenderness
• HLA-B27 positivity
• Male sex with onset after age 6
• Acute symptomatic anterior uveitis
• Family history of ankylosing spondylitis or related disorders

Unlike classic JIA-associated chronic uveitis, ERA-associated uveitis is often acute, painful, red, and photophobic.

Undifferentiated Arthritis

This includes children who do not clearly meet criteria for a single category or fulfill criteria for multiple categories.

Diagnosis

History

Many children with JIA-related uveitis have no ocular symptoms at all.

This is the reason regular ophthalmic screening is mandatory.

When symptoms are present, ask about:

• Decreased vision
• Photophobia
• Redness
• Eye pain
• Previous episodes labeled as “pink eye”
• Floaters

The absence of symptoms does not rule out active disease.

Clinical Classification

Using standard uveitis terminology, anterior inflammation may be described as:

Acute Anterior Uveitis

Sudden-onset anterior uveitis of limited duration.

Recurrent Anterior Uveitis

Repeated episodes separated by periods of inactivity without treatment.

Chronic Anterior Uveitis

Inflammation persisting for more than approximately 3 months or recurring quickly when treatment is stopped.

This is the classic form seen with JIA.

Anterior Uveitis With Vitreous Involvement

Anterior inflammation may occasionally be associated with true vitreous inflammatory cells.

Physical Examination

JIA-related uveitis is usually:

• Anterior
• Chronic
• Nongranulomatous
• Bilateral or eventually bilateral

Both eyes may become involved within months of one another.

Although traditionally considered nongranulomatous, some children can show granulomatous features.

Anterior Chamber Findings

Slit-lamp examination may demonstrate:

• Inflammatory cells
• Flare
• Posterior synechiae

Treatment decisions should be guided primarily by the cellular inflammatory activity, not by flare alone.

Persistent flare may reflect chronic breakdown of the blood-aqueous barrier even after active cellular inflammation has improved.

Posterior Synechiae

Posterior synechiae occur when the posterior iris adheres to the anterior lens capsule.

They can lead to:

• Irregular pupil
• Poor dilation
• Pupillary block
• Secondary angle closure

Preventing synechiae is an important treatment goal.

Band Keratopathy

Band keratopathy is a classic complication of chronic pediatric uveitis.

Calcium deposits accumulate within the superficial cornea, typically across the interpalpebral zone.

Severe band keratopathy may reduce vision and cause discomfort.

Cataract

Cataract is one of the most important vision-threatening complications.

It can result from:

• Chronic inflammation
• Corticosteroid treatment
• Posterior synechiae

Posterior subcapsular cataract is particularly common.

Glaucoma

Secondary glaucoma may develop from:

• Chronic inflammation
• Peripheral anterior synechiae
• Steroid response
• Trabecular damage
• Angle closure

Glaucoma can be difficult to detect in children and may progress silently.

Hypotony

Severe chronic inflammation can impair ciliary body function and lead to ocular hypotony.

Longstanding hypotony can produce:

• Maculopathy
• Structural ocular damage
• Phthisis bulbi in severe cases

Cystoid Macular Edema

CME is an important cause of decreased vision.

OCT should be obtained when central visual acuity is reduced or macular involvement is suspected.

Diagnostic Tests

Laboratory Testing

There is no laboratory test that confirms JIA-related uveitis.

JIA remains a clinical diagnosis of exclusion.

When the systemic diagnosis has not already been established, investigations may include:

• ESR
• CRP
• Platelet count
• ANA
• RF
• Anti-CCP

Testing for alternative causes may be considered when the presentation is atypical, including:

• Lyme disease
• Sarcoidosis
• Tuberculosis
• Other infectious or inflammatory disorders

Optical Coherence Tomography

OCT is particularly useful when:

• Visual acuity is reduced
• CME is suspected
• Macular structural damage needs monitoring

It provides an objective method of monitoring macular response to treatment.

Differential Diagnosis

The most important differential diagnoses include:

• Sarcoidosis
• Lyme disease
• Herpetic keratouveitis
• Trauma
• Kawasaki disease
• Other pediatric inflammatory conditions

Sarcoidosis can closely resemble JIA-associated uveitis and should be considered in atypical or granulomatous cases.

Treatment Goals

The goals are to:

• Eliminate active inflammation
• Prevent synechiae
• Preserve vision
• Minimize corticosteroid toxicity
• Prevent cataract and glaucoma
• Maintain long-term quiescence

Because children may need years of treatment, long-term safety is especially important.

First-Line Treatment

Topical Corticosteroids

Topical corticosteroids are first-line treatment for active anterior uveitis.

The dose is adjusted according to:

• Anterior chamber cell count
• Severity of inflammation
• Presence of synechiae
• Response to treatment

The goal is to achieve complete control while using the lowest effective steroid exposure.

Persistent need for frequent topical corticosteroid dosing suggests the need for steroid-sparing systemic therapy.

Cycloplegics and Mydriatics

Short-acting cycloplegics are used to:

• Prevent posterior synechiae
• Relieve ciliary spasm
• Reduce pain
• Maintain pupillary mobility

Long-term continuous cycloplegia should be used thoughtfully because blur and amblyopia can be important issues in young children.

Periocular Corticosteroids

Periocular steroid injections may occasionally be used for severe or refractory inflammation.

However, they carry significant risks, particularly:

• Cataract
• Ocular hypertension
• Glaucoma

They are therefore used selectively.

Systemic Corticosteroids

Oral or intravenous corticosteroids may be used for severe disease, but prolonged systemic steroid therapy should generally be avoided in children because of:

• Growth suppression
• Bone effects
• Metabolic complications
• Immune suppression

They are often used as temporary bridging therapy rather than as the primary long-term strategy.

Methotrexate

Methotrexate is a major first-line steroid-sparing systemic treatment for JIA-associated uveitis.

It is especially useful when:

• Topical corticosteroids cannot be reduced adequately
• Inflammation remains active
• Bilateral chronic disease is present
• Steroid toxicity is developing

Clinical response may take several weeks.

Monitoring generally includes:

• CBC
• Liver function tests

The exact monitoring schedule is coordinated with pediatric rheumatology.

Biologic Therapy

Biologic agents are important for disease that is inadequately controlled with conventional therapy.

Adalimumab

Adalimumab is strongly established as an effective therapy for JIA-associated uveitis, particularly when methotrexate alone is insufficient.

Infliximab

Infliximab can also be effective in selected refractory cases.

Etanercept

Although effective for joint disease, etanercept is not considered an effective treatment for JIA-associated uveitis and is generally not preferred when ocular inflammation is a major concern.

Other Immunomodulatory Agents

Additional steroid-sparing treatments may include:

• Mycophenolate mofetil
• Azathioprine
• Cyclosporine
• Tacrolimus

Choice depends on disease severity, response, systemic manifestations, and specialist experience.

Surgical Treatment

Cataract Surgery

Cataract is a frequent complication.

Modern management may include:

• Phacoemulsification
• Posterior capsulotomy or capsulorrhexis
• Anterior vitrectomy when appropriate
• Intraocular lens implantation in selected well-controlled cases

The most important principle is that uveitis should be well controlled before cataract surgery whenever possible.

Poorly controlled inflammation increases the risk of severe postoperative complications.

Glaucoma Surgery

When topical medications fail, surgical options may include:

• Trabeculectomy with antimetabolite
• Glaucoma drainage device

Glaucoma surgery in uveitic children can be challenging and often requires specialist management.

Band Keratopathy Treatment

Visually significant or symptomatic band keratopathy may be treated with EDTA chelation.

Recurrence can occur, particularly if inflammation remains active.

Ongoing Care

Follow-Up Recommendations

Children with JIA should undergo scheduled ophthalmic screening according to:

• Age at arthritis onset
• JIA subtype
• ANA status
• Duration of disease
• Previous history of uveitis

Screening is essential even when the child has no eye symptoms.

Patient Monitoring

Monitoring should include:

• Visual acuity
• Amblyopia assessment
• Slit-lamp examination
• Anterior chamber cell grading
• IOP measurement
• Lens evaluation
• Corneal evaluation
• Posterior segment examination
• OCT when indicated

Systemic medication toxicity must also be monitored.

Multidisciplinary Care

Management ideally involves:

• Pediatric ophthalmologist
• Pediatric rheumatologist
• Uveitis specialist when necessary

Close communication between specialists is important because arthritis activity and ocular inflammation can behave independently.

Patient and Parent Education

Parents should understand that JIA-associated uveitis is often completely asymptomatic.

A child can have serious intraocular inflammation despite:

• No pain
• No redness
• No photophobia
• No obvious visual complaint

Therefore, scheduled screening visits should not be skipped simply because the eyes appear normal.

Any episode of persistent red eye in a child with JIA should be evaluated rather than automatically assumed to be viral conjunctivitis.

Prognosis

Modern outcomes have improved significantly with:

• Earlier screening
• Aggressive control of inflammation
• Steroid-sparing immunomodulatory therapy
• Biologic treatment

Many children can retain excellent functional vision when disease is identified early and controlled adequately.

Delayed diagnosis and longstanding inflammation increase the risk of irreversible visual loss.

Complications

Important complications include:

• Cataract
• Band keratopathy
• Posterior synechiae
• Secondary glaucoma
• Cystoid macular edema
• Hypotony
• Amblyopia
• Permanent visual loss
• Phthisis bulbi in severe end-stage disease

The key clinical pearl is: JIA-related uveitis can be severe in a completely white, quiet, asymptomatic eye, so routine slit-lamp screening is essential for children at risk.